Oncopharmpod
Repotrectinib & Capivasertib
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:23:49
- Mas informaciones
Informações:
Sinopsis
FDA has approved two new kinase inhibitors: one for ROS1 (+) NSCLC and one for PIK3CA/AKT/PTEN altered breast cancer.
